| S2002 |
CZC-25146
|
CZC-25146 is a potent and selective LRRK2 inhibitor with IC50 of 4.76 nM and 6.87 nM for human wild type LRRK2 and G2019S LRRK2, respectively.
|
|
|
| S2948 |
HG-10-102-01
|
HG-10-102-01 is a potent and selective inhibitor of wild-type LRRK2 with IC50 of 23.3 nM and the G2019S mutant with IC50 of 3.2 nM.
|
|
|
| S2882 |
IKK-16
|
IKK-16 is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM in cell-free assays, respectively. IKK-16 also inhibits LRRK2 Ser935 phosphorylation in cells and LRRK2 kinase activity in vitro with IC50 of 50 nM.
|
-
Ann Rheum Dis, 2025, S0003-4967(25)04453-X
-
Nucleic Acids Res, 2025, 53(17)gkaf891
-
Cell Commun Signal, 2025, 23(1):274
|
|
| S7343 |
URMC-099
|
URMC-099 is an orally bioavailable, brain penetrant mixed lineage kinase (MLK) inhibitor with IC50 of 19 nM, 42 nM, 14 nM, and 150 nM, for MLK1, MLK2, MLK3, and DLK, respectively, and also inhibits LRRK2 activity with IC50 of 11 nM. This compound also inhibits ABL1 with IC50 of 6.8 nM. It induces autophagy.
|
-
Journal for ImmunoTherapy of Cancer, August 05, 2020, 8(2):e000494
-
Scientific Reports, April 02, 2024, 14(1):7739
-
Cell Commun Signal, 2023, 21(1):82
|
|
| S0726 |
XMD8-85 (ERK5-IN-1)
|
XMD8-85 (ERK5-IN-1) is a selective and potent inhibitor of ERK5 and LRRK2 with IC50s of 0.162 μM and 0.339 μM, respectively.
|
|
|